CV of Weihong Chen

?

Name: Chen Weihong

Unit: Department of Hematology，The First Affiliated Hospital of Shenzhen University?

Major: Treatment of hematological malignancies, bone marrow transplantation or tumor immunotherapy (enrollment direction)

Title: Professor, Chief Physician

?

Introduction:

Chen Weihong, M.D, Ph.D ., is a master tutor mentor. He is a member of: the American Society of Hematology (ASH); the American Society of Clinical Oncology (ASCO); the executive Committee of the Cellular Therapy Quality Control and Research Committee of the China Medical Quality Management Association; standing member of the Hematology Branch of the Medical Doctor Association; Executive Director of the Internal Medicine Branch of the Shenzhen Medical Doctor Association; and executive member of the Shenzhen Lymphoma Professional Committee of the China Cancer Prevention and Treatment Union.

?

Dr. Chen Weihong is an evaluation expert for the National Health and Family Planning Commission scientific research project; degree level evaluation expert for the Ministry of Education Degree Center; education expert for Shenzhen Medical Science and Technology; evaluation expert for Shenzhen Health Planning Committee scientific research projects; and evaluation expert for Shenzhen senior professional titles. He is a committee member for Shenzhen Biomedical Ethics Reviews and a member of Shenzhen Second People's Hospital Drug Clinical Trial Ethics Committee.

?

Dr. Chen Weihong mainly works in the clinical diagnosis, treatment and research of tumor immunotherapy, bone marrow transplantation and hematological malignancies. CART therapy is Chimeric Antigen Receptor T-Cell immunotherapy. He has registered two clinical trial with the National Institutes of Health in the United States. Two studies have been completed, including six involving new technologies and new projects in the hospital. In 2015, Guangdong Province took the lead in presiding over the application of the latest American technology (CART therapy) in clinical trials. Here, CART cells were used to treat 22 cases of refractory / relapsed lymphocytic leukemia, lymphoma, multiple myeloma, and solid tumors. The complete remission rate reached 70%.

?

Finally, Dr. Chen Weihong has published >20 high-level academic papers as the first or corresponding author. He is funded by Guangdong and Shenzhen Research Funds, with the total funding >850,000 yuan.

?

Research projects

1. The 2019 Shenzhen Science and Technology Plan basic research project, project number JCYJ20180228163509339, gene mutation in CART treatment refractory / recurrent lymphoma recurrence mechanism research funding 500,000 yuan, 2019/04 / 01-2022 / 03/31, Hosted the project

?

2. 2017 Shenzhen Health and Family Planning Research Project, project number 201606021, project name: CART-38 cell therapy for disease progression / recurrent multiple myeloma research，Amount: 200,000 yuan, 2017.01.01-2020.12.31, Hosted the project

?

3. The basic research project of the Shenzhen Knowledge Innovation Program in 2014, project number JCYJ20140414170821270, project name: anti-miR-155 early targeted treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, funding amount: 140,000 yuan, 2015.01.01-2016.12-31, Hosted the project

?

4. In 2004, the medical research project of Guangdong Province, project number A2004610, project name: fluorescence in situ hybridization of MLL gene rearrangement of hematological malignancies, 2005.01.01-2006.12.31, completed in 2006, Hosted the project

?

5. In 2004, the project was funded by the Shenzhen Science and Technology Plan Fund, project number 200404087, the name of the project: the establishment of MLL-related fusion gene detection method and its clinical significance, 2005.01.01-2006.12.31, the amount of funding is 20,000 yuan, completed in 2006, Hosted the project

?

Translation book

Williams Hematology 6th Edition

?

Papers published in the past five years as first or corresponding author

1. Xiaoqing Li and Weihong Chen *. Mechanisms of failure of chimeric antigen receptor T-cell therapy. Curr Opin Hematol. 2019 Nov; 26 (6): 427-433. * Corresponding author

2. Xie Mei, Chen Weihong *, Du Xin The latest progress in the treatment of acute graft versus host disease. Chinese Journal of Organ Transplantation. 2019: 40; 186-188. * Corresponding author

3. Weihong Chen, David Rizzieri, Susan Drago. Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000 / μl. J Clin Apher. 2015 Feb; 30 (1): 28-31. First author

4. Luo Changru, Chen Weihong *, Du Xin, Cai Yun, Cai Lisheng, Zhang Xiaohan. The effect and treatment of pemenase on the coagulation function of adult patients with acute lymphoblastic leukemia. China Practical Medical Journal. 2018: 8; 113-115 . * Corresponding author

5. Luo Changru, Chen Weihong *, Li Ming, Du Xin. Clinical observation of domestic granulocyte colony stimulating factor to mobilize healthy donor hematopoietic stem cells. "Chinese Medical Innovation". 2018: 15; 39-42. * Corresponding author

6. Luo Changru, Chen Weihong *, Li Ming, Du Xin, Lou Jin, Cai Yun, Wang Pengcheng, Zhang Xiaohan. Comparison of the effect of hemopoietic stem cells mobilized by SEGRI and Whirlpool healthy donors. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2018: 28; 6-9. * Corresponding author

7. Xie Mei, Chen Weihong *, Du Xin, Cai Yun, Zhang Qiaoxia, Li Ming, Luo Changru, Cai Lisheng, Zhuo Jiacai, Feng Chunrui, Li Yuzhu, Wang Pengcheng, Zhao Jiangli. MHC haploid spleen after allogeneic hematopoietic stem cell transplantation Anti-leukemia efficacy analysis. Journal of Guangxi Medical University 2017: 34 (10); 1406-1410. * Corresponding author

8. Xie Mei, Luo Changru, Chen Weihong *, Du Xin, Cai Yun, Li Yuzhu, Feng Chunrui, Liu Huanxun, Zhuo Jiacai, Li Ming, Zhang Qiaoxia, Lou Jin. Expression of plasma miR-155 in patients with acute graft-versus-host disease And its clinical significance. Journal of Guangxi Medical University, 2017: 34 (9); 1292-1295. * Corresponding author

9. Chen Weihong, Luo Changru, Du Xin, Xie Mei, Zhang Qiaoxia, Lou Jin, Zhuo Jiacai, Cai Yun, Shi Dunyun, Liu Huanxun, Feng Chunrui, Zhang Xiaohan, Weng Guangxiang. Acute allogeneic hematopoietic stem cell transplantation in mast cell tumor mice Establishment and evaluation of animal models of graft-versus-host disease. Journal of Guangxi Medical University, 2017: 34 (9); 1274-1277. First author

?

Published papers at the American Society of Hematology Annual Meeting

1.??Mei Xie, Weihong Chen*. Establishment and Evaluation of GVHD Mouse Model for Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2018 132:5681，*Corresponding author
2. Weihong Chen, Mei Xie. To Evaluate the Inhibition Leukemia Cell Effect of Haploidentical Spleen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2017 130:5491?

3. Weihong Chen, Xin Du, et al. Anti-CD19 Chimeric Antigen Receptor T Cells Improve Responses to Chemotherapy-Refractory Mantle Cell Lymphoma: A Case Report. Blood 2016 128:5393

4. Weihong Chen, Jiacai Zhuo, Xin Du. Arsenic Trioxide As a Front-Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia. Blood 2015 126:4937

5. Weihong Chen, Jiacai Zhuo, Xin Du. Detection of Rearrangements of Mixed Lineage Leukemia Gene and Its clinical relevance. Blood 2014 124:5339

?

?